Holt D, Sparrow S, Webb M
Arch Toxicol. 1985 Aug;57(3):200-4. doi: 10.1007/BF00290888.
The extensive renal tubular necrosis that results in male rats after the intravenous injection of a single, low dose of equine kidney cadmium (Cd), zinc(Zn)-metallothionein (MT) (0.2 mg MT-bound-Cd/kg body wt.) is followed within 72 h by active regeneration. With repeated administration of the same dose at 3- or 4-day intervals, lesion resolves although, at least initially, the kidney content of Cd increases progressively. At any time during treatment, about 40% of the accumulated Cd is bound as the endogenous (Cd, Cu)MT. The rate of increase in the renal Cd content is dependent on the ratio of Cd:Zn in the injected metalloprotein, and is appreciably less when the constant dose of protein-bound Cd is given as a (2.4 Cd:1 Zn)MT, than as a (3.0 Cd:1 Zn)MT. On repeated administration of the latter preparation, however, the concentration of Cd in the kidney does not attain a critical concentration, above which persistent tubular damage occurs, but reaches a maximum of about 150-160 micrograms Cd/g wet wt. (after 16 doses) and then declines. After 19 doses of the (2.4 Cd:1 Zn)MT under the same conditions, the renal Cd concentration is submaximal and is less (92 micrograms Cd/g wet wt.) than that after either 16 or 27 doses of the (3.0 Cd:1 Zn)MT. In animals that are dosed with either of the heterologous MT preparations, the first dose, although not innocuous, seems to protect the kidneys against further damage by subsequent doses. Repeated doses, however, lead to vascular changes, e.g. lymphoid infiltration, periarteriole oedema and dilation of the arcuate veins, and to dilation of the glomerular spaces.
给雄性大鼠静脉注射单次低剂量的马肾镉(Cd)、锌(Zn)-金属硫蛋白(MT)(0.2毫克与MT结合的Cd/千克体重)后,会导致广泛的肾小管坏死,72小时内会出现活跃的再生。以3天或4天的间隔重复给予相同剂量,病变会消退,尽管至少在最初,肾脏中的Cd含量会逐渐增加。在治疗的任何时候,约40%积累的Cd与内源性(Cd,Cu)MT结合。肾脏中Cd含量的增加速率取决于注射的金属蛋白中Cd:Zn的比例,当以(2.4 Cd:1 Zn)MT给予恒定剂量的蛋白结合Cd时,其增加速率明显低于以(3.0 Cd:1 Zn)MT给予时。然而,重复给予后一种制剂时,肾脏中Cd的浓度不会达到临界浓度(超过该浓度会发生持续性肾小管损伤),而是达到最大值约150 - 160微克Cd/克湿重(16次给药后),然后下降。在相同条件下给予19次(2.4 Cd:1 Zn)MT后,肾脏中Cd的浓度低于最大值,且低于给予16次或27次(3.0 Cd:1 Zn)MT后的浓度(92微克Cd/克湿重)。在用任何一种异源MT制剂给药的动物中,第一剂虽然并非无害,但似乎能保护肾脏免受后续剂量的进一步损伤。然而,重复给药会导致血管变化,如淋巴样浸润、小动脉周围水肿和弓形静脉扩张,以及肾小球间隙扩张。